This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Agilis Biotherapeutics, Inc.

Drug Names(s): AADC Gene Therapy, AGILAADC

Description: AADC Gene Therapy is an investigative gene therapy with adeno-associated virus (AAV) delivering the human aromatic L-amino acid decarboxylase (AADC) gene.

Deal Structure: Agilis and NTU
In January 2016, Agilis Biotherapeutics entered into an exclusive worldwide license agreement with National Taiwan University (NTU) for the treatment of AADC deficiency.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug